8-K: Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering

Pacira BioSciences has announced the pricing of a $250 million convertible senior notes offering due in 2029, with an option for initial purchasers to buy an additional $37.5 million.

Summary

• Pacira BioSciences has priced a private offering of $250 million in convertible senior notes due 2029.
• The initial purchasers have an option to buy an additional $37.5 million in notes.
• The notes will bear a 2.125% interest rate, payable semi-annually, and will mature on May 15, 2029.
• The company expects net proceeds of approximately $242 million, or $278.4 million if the option is fully exercised.
• Pacira plans to use approximately $191.4 million to repurchase $200 million of its 2025 convertible notes.
• Approximately $23.2 million (or $26.7 million if the option is exercised) will be used to fund capped call transactions.
• Around $25 million will be used to repurchase 837,240 shares of Pacira's common stock.
• The remaining proceeds will be used for general corporate purposes, including working capital and research and development.
• The initial conversion rate is 25.2752 shares per $1,000 principal amount of notes, equivalent to a conversion price of approximately $39.56 per share.
• The conversion rate is subject to adjustments under certain circumstances.
• Pacira may redeem the notes for cash on or after May 17, 2027, under certain conditions.
• Capped call transactions were entered into to reduce potential dilution and offset potential cash payments upon conversion of the notes.
• The cap price of the capped call transactions will initially be approximately $53.75 per share.

Sentiment

Score: 7

Explanation: The document is generally positive, indicating a strategic financial move by the company to manage debt and raise capital. The use of capped calls and share repurchases suggests a proactive approach to managing dilution and shareholder value. However, the additional debt and potential dilution are factors that temper the overall positive sentiment.

Positives

• The company is proactively managing its debt by repurchasing existing 2025 notes.
• The capped call transactions are expected to reduce potential dilution from the convertible notes.
• The company is raising capital for general corporate purposes, including research and development.

Negatives

• The company is taking on additional debt with the new convertible notes.
• The capped call transactions could increase the market price of the company's common stock or the notes.
• The conversion of the notes could lead to dilution of existing shareholders.

Risks

• The market price of Pacira's common stock or the notes could be affected by the hedging activities of the option counterparties.
• The company may not be able to complete the offering of the notes or the related transactions on the anticipated terms.
• The company's future financial performance could be impacted by the use of proceeds from the offering.

Future Outlook

Pacira intends to use the remaining net proceeds for general corporate purposes, including working capital and research and development expenditures. The company may also redeem the notes for cash on or after May 17, 2027, under certain conditions.

Industry Context

The issuance of convertible notes is a common financing strategy for biotechnology and pharmaceutical companies, allowing them to raise capital while potentially minimizing dilution if the stock price appreciates. The use of capped call transactions is also a common strategy to reduce the potential dilutive effect of convertible notes.

Comparison to Industry Standards

• The 2.125% interest rate on the convertible notes is relatively low, reflecting the current low-interest-rate environment and the company's credit profile.
• The initial conversion premium of approximately 32.5% is within the typical range for convertible notes in the biotech sector.
• The use of capped call transactions is a standard practice for companies issuing convertible notes to manage potential dilution.
• The repurchase of existing convertible notes is a common strategy to manage debt and reduce interest expenses.
• Comparable companies that have recently issued convertible notes include [insert comparable companies if known], with similar terms and conditions.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted.
• Shareholders may benefit from the company's debt management and capital raising activities.
• Creditors may be impacted by the repurchase of the 2025 notes.
• Employees may benefit from the company's continued investment in research and development.

Next Steps

• The sale of the notes to the initial purchasers is expected to settle on May 14, 2024.
• The company will use the net proceeds for debt repurchase, capped call transactions, share repurchases, and general corporate purposes.
• The option counterparties may engage in derivative transactions and purchase shares of Pacira's common stock.

Key Dates

Keywords

convertible senior notes, Pacira BioSciences, debt financing, capped call transactions, share repurchase, convertible notes, Rule 144A, private placement